Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients
Background: Many recent studies support the idea that osteopontin (OPN) can be used to predict the success of pegylated interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients. Objective: Our aim was to investigate the role of plasma OPN and its gene polymorphism at nt - 443 in respo...
Gespeichert in:
| Veröffentlicht in: | African health sciences 2017-06, Vol.17 (2), p.366-372 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 372 |
|---|---|
| container_issue | 2 |
| container_start_page | 366 |
| container_title | African health sciences |
| container_volume | 17 |
| creator | Hussein, Yousri Mostafa Alhazmi, Ayman Alzahrani, Saad Askary, Ahmad El Alghamdy, Abdulrahman Bayomy, Eman Selim, Assmaa Alghamdy, Mohammed |
| description | Background: Many recent studies support the idea that osteopontin (OPN)
can be used to predict the success of pegylated interferon (PEG IFN)
alpha-2b/ribavirin therapy in chronic HCV patients. Objective: Our aim
was to investigate the role of plasma OPN and its gene polymorphism at
nt - 443 in response to PEG IFN in Saudi patients with chronic
HCV. Methods: Blood was collected from 87 patients with chronic
hepatitis C before treatment, then patients received PEG IFN α2b
plus ribavirin combination therapy. Another 25 healthy subjects,
matched for age and sex to patients, were enrolled as controls. Single
nucleotide polymorphism (SNP) in OPN at nt - 443 and its blood
level were analyzed. Results: The frequency of patients who reached
sustained virological response (SVR) was increased in patients with T/T
at nt - 443 than in those with C/C or C/T. Also the frequency of
T allele was increased in responders than in non-responders. However,
this increase was not statistically significant. The blood level of OPN
was significantly increased in non-responders
(Mean±SD=37.21±3.9) in comparison to responders
(Mean±SD=33.22±4.1). Conclusion: Osteopontin blood level can
be considered as a reliable predictor to PEG IFN α2b plus
ribavirin therapy in chronic HCV Saudi Patients. |
| doi_str_mv | 10.4314/ahs.v17i2.10 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5637021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1955061775</sourcerecordid><originalsourceid>FETCH-LOGICAL-b385t-97206c6d33f7f0f740d9b5a2be660a5a3027c5a1bc41244a7043fbe544284e403</originalsourceid><addsrcrecordid>eNpVkctv1EAMxiMEog-4cUZz5EAWz3tzQapWhVaq1AOP68hJnGYgyYSZ2Ur97xnYdgUnW_5--mzrq6o3HDZKcvUBx7S559aLDYdn1Sm3oqlBg3xeerOF2jSgT6qzlH4ACMMb_rI6EQ0YISU_rebblCmsYcl-YZgYshnjT4psCJFFSkVJxHJgK909TJipZ37JFAeKYWEX0zpiLVqWI2GeaclFZbuxaL5jV7vv7Avue89WzL6I6VX1YsAp0evHel59-3T5dXdV39x-vt5d3NSt3OpcN1aA6Uwv5WAHGKyCvmk1ipaMAdQoQdhOI287xYVSaEHJoSWtlNgqUiDPq48H33XfztR3ZXfEya3Rl-8eXEDv_lcWP7q7cO-0kRYELwbvHg1i-LWnlN3sU0fThAuFfXK80RoMt1YX9P0B7WJIKdJwXMPB_UnIlYTc34TKpOBv_z3tCD9FUoDNAWh9mPxCR6KLHt3TsFiOiZfHjfwN1kGfjA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1955061775</pqid></control><display><type>article</type><title>Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients</title><source>African Journals Online (Open Access)</source><source>Bioline International</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Hussein, Yousri Mostafa ; Alhazmi, Ayman ; Alzahrani, Saad ; Askary, Ahmad El ; Alghamdy, Abdulrahman ; Bayomy, Eman ; Selim, Assmaa ; Alghamdy, Mohammed</creator><creatorcontrib>Hussein, Yousri Mostafa ; Alhazmi, Ayman ; Alzahrani, Saad ; Askary, Ahmad El ; Alghamdy, Abdulrahman ; Bayomy, Eman ; Selim, Assmaa ; Alghamdy, Mohammed</creatorcontrib><description>Background: Many recent studies support the idea that osteopontin (OPN)
can be used to predict the success of pegylated interferon (PEG IFN)
alpha-2b/ribavirin therapy in chronic HCV patients. Objective: Our aim
was to investigate the role of plasma OPN and its gene polymorphism at
nt - 443 in response to PEG IFN in Saudi patients with chronic
HCV. Methods: Blood was collected from 87 patients with chronic
hepatitis C before treatment, then patients received PEG IFN α2b
plus ribavirin combination therapy. Another 25 healthy subjects,
matched for age and sex to patients, were enrolled as controls. Single
nucleotide polymorphism (SNP) in OPN at nt - 443 and its blood
level were analyzed. Results: The frequency of patients who reached
sustained virological response (SVR) was increased in patients with T/T
at nt - 443 than in those with C/C or C/T. Also the frequency of
T allele was increased in responders than in non-responders. However,
this increase was not statistically significant. The blood level of OPN
was significantly increased in non-responders
(Mean±SD=37.21±3.9) in comparison to responders
(Mean±SD=33.22±4.1). Conclusion: Osteopontin blood level can
be considered as a reliable predictor to PEG IFN α2b plus
ribavirin therapy in chronic HCV Saudi Patients.</description><identifier>ISSN: 1680-6905</identifier><identifier>EISSN: 1729-0503</identifier><identifier>EISSN: 1680-6905</identifier><identifier>DOI: 10.4314/ahs.v17i2.10</identifier><identifier>PMID: 29062331</identifier><language>eng</language><publisher>Uganda: Makerere University Medical School</publisher><subject>HCV ; OPN ; PEG IFN ; RT-PCR ; SNP ; SVR</subject><ispartof>African health sciences, 2017-06, Vol.17 (2), p.366-372</ispartof><rights>Copyright 2017 - African Health Sciences</rights><rights>Copyright © Makerere Medical School, Uganda 2017 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b385t-97206c6d33f7f0f740d9b5a2be660a5a3027c5a1bc41244a7043fbe544284e403</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637021/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637021/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,79426</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29062331$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hussein, Yousri Mostafa</creatorcontrib><creatorcontrib>Alhazmi, Ayman</creatorcontrib><creatorcontrib>Alzahrani, Saad</creatorcontrib><creatorcontrib>Askary, Ahmad El</creatorcontrib><creatorcontrib>Alghamdy, Abdulrahman</creatorcontrib><creatorcontrib>Bayomy, Eman</creatorcontrib><creatorcontrib>Selim, Assmaa</creatorcontrib><creatorcontrib>Alghamdy, Mohammed</creatorcontrib><title>Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients</title><title>African health sciences</title><addtitle>Afr Health Sci</addtitle><description>Background: Many recent studies support the idea that osteopontin (OPN)
can be used to predict the success of pegylated interferon (PEG IFN)
alpha-2b/ribavirin therapy in chronic HCV patients. Objective: Our aim
was to investigate the role of plasma OPN and its gene polymorphism at
nt - 443 in response to PEG IFN in Saudi patients with chronic
HCV. Methods: Blood was collected from 87 patients with chronic
hepatitis C before treatment, then patients received PEG IFN α2b
plus ribavirin combination therapy. Another 25 healthy subjects,
matched for age and sex to patients, were enrolled as controls. Single
nucleotide polymorphism (SNP) in OPN at nt - 443 and its blood
level were analyzed. Results: The frequency of patients who reached
sustained virological response (SVR) was increased in patients with T/T
at nt - 443 than in those with C/C or C/T. Also the frequency of
T allele was increased in responders than in non-responders. However,
this increase was not statistically significant. The blood level of OPN
was significantly increased in non-responders
(Mean±SD=37.21±3.9) in comparison to responders
(Mean±SD=33.22±4.1). Conclusion: Osteopontin blood level can
be considered as a reliable predictor to PEG IFN α2b plus
ribavirin therapy in chronic HCV Saudi Patients.</description><subject>HCV</subject><subject>OPN</subject><subject>PEG IFN</subject><subject>RT-PCR</subject><subject>SNP</subject><subject>SVR</subject><issn>1680-6905</issn><issn>1729-0503</issn><issn>1680-6905</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>RBI</sourceid><recordid>eNpVkctv1EAMxiMEog-4cUZz5EAWz3tzQapWhVaq1AOP68hJnGYgyYSZ2Ur97xnYdgUnW_5--mzrq6o3HDZKcvUBx7S559aLDYdn1Sm3oqlBg3xeerOF2jSgT6qzlH4ACMMb_rI6EQ0YISU_rebblCmsYcl-YZgYshnjT4psCJFFSkVJxHJgK909TJipZ37JFAeKYWEX0zpiLVqWI2GeaclFZbuxaL5jV7vv7Avue89WzL6I6VX1YsAp0evHel59-3T5dXdV39x-vt5d3NSt3OpcN1aA6Uwv5WAHGKyCvmk1ipaMAdQoQdhOI287xYVSaEHJoSWtlNgqUiDPq48H33XfztR3ZXfEya3Rl-8eXEDv_lcWP7q7cO-0kRYELwbvHg1i-LWnlN3sU0fThAuFfXK80RoMt1YX9P0B7WJIKdJwXMPB_UnIlYTc34TKpOBv_z3tCD9FUoDNAWh9mPxCR6KLHt3TsFiOiZfHjfwN1kGfjA</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Hussein, Yousri Mostafa</creator><creator>Alhazmi, Ayman</creator><creator>Alzahrani, Saad</creator><creator>Askary, Ahmad El</creator><creator>Alghamdy, Abdulrahman</creator><creator>Bayomy, Eman</creator><creator>Selim, Assmaa</creator><creator>Alghamdy, Mohammed</creator><general>Makerere University Medical School</general><general>Makerere Medical School</general><scope>RBI</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170601</creationdate><title>Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients</title><author>Hussein, Yousri Mostafa ; Alhazmi, Ayman ; Alzahrani, Saad ; Askary, Ahmad El ; Alghamdy, Abdulrahman ; Bayomy, Eman ; Selim, Assmaa ; Alghamdy, Mohammed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b385t-97206c6d33f7f0f740d9b5a2be660a5a3027c5a1bc41244a7043fbe544284e403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>HCV</topic><topic>OPN</topic><topic>PEG IFN</topic><topic>RT-PCR</topic><topic>SNP</topic><topic>SVR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hussein, Yousri Mostafa</creatorcontrib><creatorcontrib>Alhazmi, Ayman</creatorcontrib><creatorcontrib>Alzahrani, Saad</creatorcontrib><creatorcontrib>Askary, Ahmad El</creatorcontrib><creatorcontrib>Alghamdy, Abdulrahman</creatorcontrib><creatorcontrib>Bayomy, Eman</creatorcontrib><creatorcontrib>Selim, Assmaa</creatorcontrib><creatorcontrib>Alghamdy, Mohammed</creatorcontrib><collection>Bioline International</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>African health sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hussein, Yousri Mostafa</au><au>Alhazmi, Ayman</au><au>Alzahrani, Saad</au><au>Askary, Ahmad El</au><au>Alghamdy, Abdulrahman</au><au>Bayomy, Eman</au><au>Selim, Assmaa</au><au>Alghamdy, Mohammed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients</atitle><jtitle>African health sciences</jtitle><addtitle>Afr Health Sci</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>17</volume><issue>2</issue><spage>366</spage><epage>372</epage><pages>366-372</pages><issn>1680-6905</issn><eissn>1729-0503</eissn><eissn>1680-6905</eissn><abstract>Background: Many recent studies support the idea that osteopontin (OPN)
can be used to predict the success of pegylated interferon (PEG IFN)
alpha-2b/ribavirin therapy in chronic HCV patients. Objective: Our aim
was to investigate the role of plasma OPN and its gene polymorphism at
nt - 443 in response to PEG IFN in Saudi patients with chronic
HCV. Methods: Blood was collected from 87 patients with chronic
hepatitis C before treatment, then patients received PEG IFN α2b
plus ribavirin combination therapy. Another 25 healthy subjects,
matched for age and sex to patients, were enrolled as controls. Single
nucleotide polymorphism (SNP) in OPN at nt - 443 and its blood
level were analyzed. Results: The frequency of patients who reached
sustained virological response (SVR) was increased in patients with T/T
at nt - 443 than in those with C/C or C/T. Also the frequency of
T allele was increased in responders than in non-responders. However,
this increase was not statistically significant. The blood level of OPN
was significantly increased in non-responders
(Mean±SD=37.21±3.9) in comparison to responders
(Mean±SD=33.22±4.1). Conclusion: Osteopontin blood level can
be considered as a reliable predictor to PEG IFN α2b plus
ribavirin therapy in chronic HCV Saudi Patients.</abstract><cop>Uganda</cop><pub>Makerere University Medical School</pub><pmid>29062331</pmid><doi>10.4314/ahs.v17i2.10</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1680-6905 |
| ispartof | African health sciences, 2017-06, Vol.17 (2), p.366-372 |
| issn | 1680-6905 1729-0503 1680-6905 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5637021 |
| source | African Journals Online (Open Access); Bioline International; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | HCV OPN PEG IFN RT-PCR SNP SVR |
| title | Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T12%3A24%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Osteopontin%20as%20a%20marker%20for%20response%20to%20pegylated%20interferon%20Alpha-2b%20treatment%20in%20Chronic%20HCV%20Saudi%20patients&rft.jtitle=African%20health%20sciences&rft.au=Hussein,%20Yousri%20Mostafa&rft.date=2017-06-01&rft.volume=17&rft.issue=2&rft.spage=366&rft.epage=372&rft.pages=366-372&rft.issn=1680-6905&rft.eissn=1729-0503&rft_id=info:doi/10.4314/ahs.v17i2.10&rft_dat=%3Cproquest_pubme%3E1955061775%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1955061775&rft_id=info:pmid/29062331&rfr_iscdi=true |